Skip Navigation
Skip to contents

KMJ : Kosin Medical Journal

OPEN ACCESS
SEARCH
Search

Articles

Page Path
HOME > Kosin Med J > Volume 41(3); 2026 > Article
Case report
Pneumocystis jirovecii pneumonia in children without known immunodeficiency: a five-case series
Minji Kimorcid, Jeong Eun Kangorcid, Younga Kimorcid
Kosin Medical Journal 2026;41(3):260-265.
DOI: https://doi.org/10.7180/kmj.26.158
Published online: July 21, 2026

Department of Pediatrics, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea

Corresponding Author: Younga Kim, MD Department of Pediatrics, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, 20 Geumo-ro, Mulgeum-eup, Yangsan 50612, Korea Tel: +82-55-360-3516 Fax: +82-55-360-2181 E-mail: youngflo@pusan.ac.kr
• Received: February 10, 2026   • Revised: April 17, 2026   • Accepted: April 28, 2026

© 2026 Kosin University College of Medicine.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 887 Views
  • 9 Download
prev next
  • Pneumocystis jirovecii pneumonia (PJP) is classically associated with primary immunodeficiency, malignancy, or immunosuppressive therapy. However, PJP may also occur in patients without known immunodeficiency when host defenses are functionally impaired. Alterations in cell-mediated immunity related to malnutrition, metabolic stress, or critical illness may be associated with increased susceptibility to opportunistic infections such as PJP. We report five pediatric cases of clinically probable PJP, identified on the basis of positive polymerase chain reaction results from respiratory specimens together with compatible clinical features and responses to treatment. None of the patients had a diagnosis of primary immunodeficiency or active malignancy. Two infants had nutritional vulnerability related to restrictive diets and micronutrient deficiencies, whereas three older children developed PJP in the context of malnutrition, severe metabolic stress, or critical illness with baseline ventilator dependence. All patients experienced hypoxemic respiratory failure or difficulty with ventilator weaning and showed clinical improvement after treatment with trimethoprim-sulfamethoxazole. These cases highlight that PJP can occur in children without known immunodeficiency in the setting of malnutrition, metabolic stress, or critical illness.
Pneumocystis jirovecii pneumonia (PJP) is an opportunistic infection that typically occurs in patients with impaired cell-mediated immunity, such as those with primary immunodeficiency, malignancy, or exposure to immunosuppressive therapy [1-3].
Although PJP is usually associated with recognized immunocompromising conditions, it may also occur in patients without known immunodeficiency. Historically, PJP was also described in malnourished infants and undernourished populations, suggesting that functional impairment of host defense alone may be sufficient for disease development [1]. Previous reports have described such cases in the setting of severe malnutrition, micronutrient deficiency, and other clinical conditions affecting host defense [4-8]. These observations suggest that opportunistic infections such as PJP may be considered when respiratory illness is not fully explained by more common etiologies.
We describe five pediatric cases of clinically probable PJP occurring without known immunodeficiency and highlight clinical contexts associated with acquired immune vulnerability.
Ethical statements: This case series was approved by the Institutional Review Board (IRB) of Pusan National University Yangsan Hospital (IRB No. 05-2023-007), with informed consent waived due to the retrospective design.
We reviewed patients aged <18 years who were treated at a single tertiary center between July 2012 and December 2022 and had P. jirovecii detected by polymerase chain reaction (PCR) performed on respiratory specimens. Patients were excluded if they had primary immunodeficiency, active malignancy, or exposure to immunosuppressive therapy, including systemic corticosteroids for more than 2 weeks.
Cases were included if the clinical presentation was compatible with PJP, based on respiratory failure or difficulty with ventilator weaning, compatible imaging findings, absence of an alternative pathogen, and improvement after treatment with trimethoprim-sulfamethoxazole (TMP-SMX).
Of the 60 patients with positive P. jirovecii PCR results, five met these criteria and were included in the study. Because bronchoalveolar lavage (BAL), microscopy, and serum (1–3)-β-D-glucan testing were not consistently performed, all cases were regarded as clinically probable PJP. The clinical characteristics, laboratory findings, and outcomes of all five patients are summarized in Table 1, and the radiologic findings are shown in Figs. 1 and 2.
1. Case 1
A 4-month-old girl with maple syrup urine disease, an inherited disorder of branched-chain amino acid metabolism, was diagnosed at 7 days of life and was receiving a restrictive, specialized formula diet.
Three weeks before admission, she developed cough, sputum production, and reduced oral intake. Her condition progressed to hypoxemic respiratory failure requiring invasive mechanical ventilation (MV). Chest radiography showed diffuse bilateral haziness, which had also been noted on imaging obtained 3 weeks earlier. Laboratory evaluations revealed markedly elevated lactate dehydrogenase (LDH) levels. Tracheal aspirate PCR was positive for P. jirovecii. Following initiation of TMP-SMX, her respiratory status gradually improved, and she was weaned from MV after 11 days. She is currently 6 years old and remains under follow-up with a balanced nutritional regimen.
2. Case 2
A 5-month-old boy with bronchopulmonary dysplasia, born at 28+2 weeks of gestation (birth weight, 1,200 g), was transferred to our hospital because he could not be weaned from MV despite receiving approximately 3 weeks of treatment for presumed pneumonia. He had been fed an amino acid-based hypoallergenic formula exclusively for 3 months because of frequent regurgitation.
Evaluation revealed rickets with hypocalcemia (6.4 mg/dL), hypophosphatemia (3.3 mg/dL), secondary hyperparathyroidism (parathyroid hormone, 106 pg/mL), vitamin D insufficiency (25-hydroxyvitamin D, 27.7 ng/mL), and compatible radiologic findings (Fig. 2), which were attributed to prolonged exclusive elemental formula feeding [9]. Calcitriol and calcium supplementation were initiated.
Chest radiography showed predominantly consolidative changes with nodular findings rather than the classic diffuse ground-glass pattern typically observed in patients with bronchopulmonary dysplasia. On hospital day (HD) 7, tracheal aspirate PCR was positive for P. jirovecii. After initiation of TMP-SMX, oxygenation gradually improved, allowing successful liberation from MV after 11 days and discharge 2 weeks later. Concurrent cytomegalovirus (CMV) infection was identified by both blood PCR (683 copies/mL) and tracheal aspirate PCR and was treated with ganciclovir. CMV pneumonitis was considered less likely based on the low viral load, atypical radiologic findings, and the clinical course.
3. Case 3
A 15-year-old girl with anorexia nervosa had experienced progressive symptoms for approximately 2 years and developed profound weight loss from 57 to 25 kg, consistent with severe malnutrition. On HD 11, she developed acute dyspnea requiring MV.
Chest radiography findings rapidly worsened, PJP was clinically suspected, and TMP-SMX was initiated empirically. At admission, zinc deficiency (52.47 µg/dL) and vitamin D deficiency (25-hydroxyvitamin D, 5.48 ng/mL) were noted, and appropriate supplementation was initiated. P. jirovecii was detected by PCR 5 days later. She required MV for 7 days and was successfully extubated, followed by transfer to the general ward after 2 weeks and discharge after 2 months with weight gain to 30 kg.
4. Case 4
A 3-year-old boy with Leigh disease, a mitochondrial disorder characterized by progressive neurodegeneration and multiorgan dysfunction, was diagnosed at 18 months of age due to developmental delay and was receiving home MV. He was hospitalized for worsening hypoxemia accompanied by pleural effusion and acute kidney injury, requiring escalation of ventilatory support. During the preceding 5 months, he had recurrent hypoalbuminemia related to proteinuria, requiring intermittent albumin supplementation, along with progressive leukopenia, which had worsened in the 2 weeks before admission (<2,000/µL), raising concern for advancing multiorgan dysfunction.
On HD 7, P. jirovecii was detected by PCR, and his oxygenation improved after initiation of TMP-SMX, allowing a return to baseline ventilator settings. He was subsequently transferred to the general ward. However, multiorgan failure progressed, and he died 1 month later.
5. Case 5
A 13-year-old girl presented with hyperosmolar hyperglycemic syndrome complicated by refractory shock and multiorgan failure and was newly diagnosed with type 2 diabetes mellitus. On HD 22, the patient developed fever, cough, and respiratory distress, requiring escalation of respiratory support from low-flow oxygen to a high-flow nasal cannula. Chest radiography revealed diffuse ground-glass opacities. TMP-SMX was initiated for suspected PJP, and sputum PCR testing later confirmed P. jirovecii, with subsequent clinical improvement.
6. Diagnostic approach and treatment response
All five patients developed significant respiratory compromise requiring intensive care support. Alternative respiratory pathogens were evaluated as clinically indicated but did not fully explain the clinical course. P. jirovecii was detected by PCR within 3–5 days using tracheal aspirates or induced sputum. In two patients, TMP-SMX was initiated empirically prior to microbiological confirmation. All patients received treatment for 11–14 days and showed clinical improvement, including successful weaning from respiratory support and return to baseline status when applicable.
This case series suggests that PJP may occur outside the classic high-risk groups when host defenses are compromised by acquired conditions. Although none of the patients was diagnosed with immunodeficiency, PJP was not initially suspected in most cases and was considered only when respiratory deterioration was not fully explained by more common etiologies.
Across the cases, shared features included significant respiratory compromise requiring intensive care and clinical conditions that could affect host defense, such as malnutrition, restrictive or imbalanced nutritional intake, metabolic stress, and critical illness. These factors were not identified a priori but became relevant in the context of unexpected or disproportionate clinical progression.
Malnutrition and related nutritional deficiencies, as well as critical illness, have been associated with impaired cell-mediated immunity, dysregulated inflammatory responses, and compromised mucosal barrier integrity [1,10-13]. In addition, systemic inflammatory states such as sepsis and acute respiratory distress syndrome may lead to immune dysregulation characterized by initial hyperinflammation followed by immune suppression, potentially increasing susceptibility to opportunistic infections [14,15]. In our series, these factors may have acted in combination. Nutritional compromise was evident in several patients, and acute metabolic stress or critical illness likely contributed to further immune dysregulation. These conditions, rather than the underlying diagnoses themselves, may have played a role in the development of PJP.
Diagnosing PJP in children without known immunodeficiency can be challenging, because clinical and radiologic findings are heterogeneous and laboratory markers may be nonspecific [16]. In our series, LDH elevation was observed in only one patient, and imaging findings ranged from diffuse ground-glass opacities to consolidative changes, consistent with prior reports [2,17].
Case 2 highlights the complexity of interpretation in the presence of CMV coinfection. Although CMV was detected, it was considered less likely to be the primary cause of pneumonitis based on clinical features. Previous studies suggest that CMV coinfection may reflect underlying immune dysregulation rather than an incidental finding [17-19].
A limitation of this study is that additional diagnostic evaluations, including BAL, microscopy, and serum β-D-glucan testing, were not performed in all patients due to the clinical constraints of critically ill children. In addition, the diagnostic role of β-D-glucan in pediatric populations remains uncertain [20]. Therefore, the diagnosis was based on a composite clinical approach integrating clinical, radiologic, and PCR findings with treatment response, and should be interpreted as clinically probable PJP. The possibility of colonization cannot be fully excluded. The observed association between acquired immune vulnerability and PJP should be interpreted with caution and considered hypothesis-generating.
In conclusion, PJP may be considered in children without known immunodeficiency when respiratory deterioration is not fully explained by more common conditions, particularly in the presence of malnutrition, metabolic stress, or critical illness. Early clinical suspicion, timely PCR testing, and prompt initiation of appropriate therapy may support improved clinical outcomes.

Conflicts of interest

No potential conflict of interest relevant to this article was reported.

Funding

This work was supported by a 2-Year Research Grant of Pusan National University.

Author contributions

Conceptualization: YK. Data curation: JEK. Formal analysis: MK. Funding acquisition: YK. Investigation: MK. Methodology: JEK. Project administration: YK. Resources: MK. Software: JEK. Supervision: YK. Validation: YK. Visualization: JEK. Writing-original draft: MK, YK. Writing-review & editing: JEK, YK. All authors have read and approved the final manuscript.

Fig. 1.
Chest radiographs of cases 1, 3, 4, and 5. Panels A–H show paired pretreatment and follow-up images for each case: (A, B) case 1; (C, D) case 3; (E, F) case 4; (G, H) case 5. Follow-up radiographs were obtained 10 days to 2 weeks after initiation of trimethoprim-sulfamethoxazole therapy and demonstrate interval improvement in the radiographic abnormalities.
kmj-26-158f1.jpg
Fig. 2.
Radiographic findings in case 2. (A) Chest radiograph obtained on the day of admission. (B, b) Follow-up chest radiographs obtained 1 month later; panel b shows a rachitic rosary. (C) Anteroposterior radiograph of the left wrist showing fractures of the distal radius and ulnar styloid process. (D, d) Anteroposterior radiographs of the knee demonstrating a fracture of the right distal femoral metaphysis.
kmj-26-158f2.jpg
Table 1.
Clinical characteristics, laboratory findings, and outcomes of the five patients
Variable Case 1 Case 2 Case 3 Case 4 Case 5
Age/sex 4 mo/female 5 mo/male 15 yr/female 3 yr/male 13 yr/female
Duration of respiratory symptoms (day) 21 (cough, tachypnea) 21 (failed ventilator weaning) 2 (dyspnea) 14 (gradual ventilator worsening) 3 (fever, cough, dyspnea)
Underlying condition Maple syrup urine disease Preterm birth, vitamin D deficiency rickets Anorexia nervosa, severe malnutrition Leigh disease with chronic critical illness Type 2 diabetes mellitus, HHS, multiorgan failure
WBC (/µL) 20,730 1,620 3,990 1,890 12,860
ANC (/µL) 14,096 930 3,070 210 10,950
ALC (/µL) 4,354 540 490 990 660
CD4⁺ T cells NA NA NA 37.0%/366 cells/µLa) NA
Hemoglobin (g/dL) 7.9 9.6 8.0 8.6 8.3
Platelet count (×10³/µL) 804 134 100 128 275
AST (IU/L) 37 43 129 17 37
ALT (IU/L) 78 21 126 30 9
LDH (IU/L) 1,855 NA 361 128 330
Total protein (g/dL) 4.1 4.0 4.7 5.0 6.0
Albumin (g/dL) 2.3 2.9 2.9 2.9 3.4
CRP (mg/dL) 3.03 2.44 3.12 4.62 2.68
Respiratory specimen for PCR Tracheal aspirate Tracheal aspirate Tracheal aspirate Tracheal aspirate Induced sputum
CMV PCR (blood) Negative Positive Negative Negative NA
Respiratory support after treatment (day) MV, 11 MV, 11 MV, 7 MV, 9 HFNC, 3

Laboratory values represent results obtained at or closest to the time of Pneumocystis jirovecii PCR testing or trimethoprim-sulfamethoxazole (TMP-SMX) initiation.

HHS, hyperosmolar hyperglycemic syndrome; WBC, white blood cell; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; NA, not available; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; CRP, C-reactive protein; PCR, polymerase chain reaction; CMV, cytomegalovirus; MV, mechanical ventilation; HFNC, high-flow nasal cannula.

a)CD4⁺ T-cell subset analysis was available only for case 4 and was obtained at the time of TMP-SMX initiation.

  • 1. Catherinot E, Lanternier F, Bougnoux ME, Lecuit M, Couderc LJ, Lortholary O. Pneumocystis jirovecii pneumonia. Infect Dis Clin North Am 2010;24:107–38.ArticlePubMed
  • 2. Avino LJ, Naylor SM, Roecker AM. Pneumocystis jirovecii pneumonia in the non-HIV-infected population. Ann Pharmacother 2016;50:673–9.ArticlePubMedPDF
  • 3. Morris A, Wei K, Afshar K, Huang L. Epidemiology and clinical significance of Pneumocystis colonization. J Infect Dis 2008;197:10–7.ArticlePubMed
  • 4. Hanachi M, Bohem V, Bemer P, Kayser N, de Truchis P, Melchior JC. Negative role of malnutrition in cell-mediated immune response: Pneumocystis jirovecii pneumonia (PCP) in a severely malnourished, HIV-negative patient with anorexia nervosa. Clin Nutr ESPEN 2018;25:163–5.ArticlePubMed
  • 5. Vidmar P, Altenburg J, van Leeuwen EM, van Bellegem AC, Verhoef C, de Bree GJ, et al. Lymphocyte subsets and the increased risk for opportunistic infections in severe restrictive anorexia nervosa. J Eat Disord 2025;13:84.ArticlePubMedPMCPDF
  • 6. Attalla El Halabieh N, Petrillo E, Laviano A, Delfino M, Rossi Fanelli F. A case of Pneumocystis jirovecii pneumonia in a severely malnourished, HIV-negative patient: a role for malnutrition in opportunistic infections? JPEN J Parenter Enteral Nutr 2016;40:722–4.ArticlePubMed
  • 7. Crighton G, Haeusler G, Pati N, Connell TG. Pneumocystis jiroveci pneumonia in an infant with severe folate deficiency. Pediatr Infect Dis J 2011;30:721–3.ArticlePubMed
  • 8. Calderon EJ, Rivero L, Respaldiza N, Morilla R, Montes-Cano MA, Friaza V, et al. Systemic inflammation in patients with chronic obstructive pulmonary disease who are colonized with Pneumocystis jiroveci. Clin Infect Dis 2007;45:e17–9.ArticlePubMed
  • 9. Uday S, Sakka S, Davies JH, Randell T, Arya V, Brain C, et al. Elemental formula associated hypophosphataemic rickets. Clin Nutr 2019;38:2246–50.ArticlePubMed
  • 10. Rytter MJ, Kolte L, Briend A, Friis H, Christensen VB. The immune system in children with malnutrition: a systematic review. PLoS One 2014;9:e105017.ArticlePubMedPMC
  • 11. Delano MJ, Ward PA. The immune system’s role in sepsis progression, resolution, and long-term outcome. Immunol Rev 2016;274:330–53.ArticlePubMedPMCPDF
  • 12. Martin-Loeches I, David S, Pene F, Kreitmann L, Russel L, Puxty K, et al. Advocating for the recognition of underlying immunosuppression in critical illness. EClinicalMedicine 2025;85:103300.ArticlePubMedPMC
  • 13. de Jager P, Smith O, Pool R, Bolon S, Richards GA. Review of the pathophysiology and prognostic biomarkers of immune dysregulation after severe injury. J Trauma Acute Care Surg 2021;90:e21–30.ArticlePubMed
  • 14. Mehta Y, Dixit SB, Zirpe K, Sud R, Gopal PB, Koul PA, et al. Therapeutic approaches in modulating the inflammatory and immunological response in patients with sepsis, acute respiratory distress syndrome, and pancreatitis: an expert opinion review. Cureus 2021;13:e18393.ArticlePubMedPMC
  • 15. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 2013;13:862–74.ArticlePubMedPMCPDF
  • 16. Quist J, Hill AR. Serum lactate dehydrogenase (LDH) in Pneumocystis carinii pneumonia, tuberculosis, and bacterial pneumonia. Chest 1995;108:415–8.ArticlePubMed
  • 17. Jung S, Hwang E, Kang J, Kim Y. Clinical outcomes and risk factors of Pneumocystis jirovecii pneumonia in pediatric acute lymphoblastic leukemia: a 10-year single-center study. Arch Pediatr Crit Care 2025;3:23–30.ArticlePDF
  • 18. Korkmaz Ekren P, Toreyin ZN, Nahid P, Doskaya M, Caner A, Turgay N, et al. The association between Cytomegalovirus co-infection with Pneumocystis pneumonia and mortality in immunocompromised non-HIV patients. Clin Respir J 2018;12:2590–7.ArticlePubMedPMC
  • 19. Yu Q, Jia P, Su L, Zhao H, Que C. Outcomes and prognostic factors of non-HIV patients with pneumocystis jirovecii pneumonia and pulmonary CMV co-infection: a retrospective cohort study. BMC Infect Dis 2017;17:392.ArticlePubMedPDF
  • 20. Ferreras-Antolin L, Borman A, Diederichs A, Warris A, Lehrnbecher T. Serum beta-D-glucan in the diagnosis of invasive fungal disease in neonates, children and adolescents: a critical analysis of current data. J Fungi (Basel) 2022;8:1262.ArticlePubMedPMCPDF

Figure & Data

References

    Citations

    Citations to this article as recorded by  

      • PubReader PubReader
      • ePub LinkePub Link
      • Cite
        CITE
        export Copy
        Close
      • Download Citation
        Download Citation
        Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

        Format:
        • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
        • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
        Include:
        • Citation for the content below
        Pneumocystis jirovecii pneumonia in children without known immunodeficiency: a five-case series
        Kosin Med J. 2026;41(3):260-265.   Published online July 21, 2026
        Close
      • XML DownloadXML Download
      Figure
      • 0
      • 1
      Pneumocystis jirovecii pneumonia in children without known immunodeficiency: a five-case series
      Image Image
      Fig. 1. Chest radiographs of cases 1, 3, 4, and 5. Panels A–H show paired pretreatment and follow-up images for each case: (A, B) case 1; (C, D) case 3; (E, F) case 4; (G, H) case 5. Follow-up radiographs were obtained 10 days to 2 weeks after initiation of trimethoprim-sulfamethoxazole therapy and demonstrate interval improvement in the radiographic abnormalities.
      Fig. 2. Radiographic findings in case 2. (A) Chest radiograph obtained on the day of admission. (B, b) Follow-up chest radiographs obtained 1 month later; panel b shows a rachitic rosary. (C) Anteroposterior radiograph of the left wrist showing fractures of the distal radius and ulnar styloid process. (D, d) Anteroposterior radiographs of the knee demonstrating a fracture of the right distal femoral metaphysis.
      Pneumocystis jirovecii pneumonia in children without known immunodeficiency: a five-case series
      Variable Case 1 Case 2 Case 3 Case 4 Case 5
      Age/sex 4 mo/female 5 mo/male 15 yr/female 3 yr/male 13 yr/female
      Duration of respiratory symptoms (day) 21 (cough, tachypnea) 21 (failed ventilator weaning) 2 (dyspnea) 14 (gradual ventilator worsening) 3 (fever, cough, dyspnea)
      Underlying condition Maple syrup urine disease Preterm birth, vitamin D deficiency rickets Anorexia nervosa, severe malnutrition Leigh disease with chronic critical illness Type 2 diabetes mellitus, HHS, multiorgan failure
      WBC (/µL) 20,730 1,620 3,990 1,890 12,860
      ANC (/µL) 14,096 930 3,070 210 10,950
      ALC (/µL) 4,354 540 490 990 660
      CD4⁺ T cells NA NA NA 37.0%/366 cells/µLa) NA
      Hemoglobin (g/dL) 7.9 9.6 8.0 8.6 8.3
      Platelet count (×10³/µL) 804 134 100 128 275
      AST (IU/L) 37 43 129 17 37
      ALT (IU/L) 78 21 126 30 9
      LDH (IU/L) 1,855 NA 361 128 330
      Total protein (g/dL) 4.1 4.0 4.7 5.0 6.0
      Albumin (g/dL) 2.3 2.9 2.9 2.9 3.4
      CRP (mg/dL) 3.03 2.44 3.12 4.62 2.68
      Respiratory specimen for PCR Tracheal aspirate Tracheal aspirate Tracheal aspirate Tracheal aspirate Induced sputum
      CMV PCR (blood) Negative Positive Negative Negative NA
      Respiratory support after treatment (day) MV, 11 MV, 11 MV, 7 MV, 9 HFNC, 3
      Table 1. Clinical characteristics, laboratory findings, and outcomes of the five patients

      Laboratory values represent results obtained at or closest to the time of Pneumocystis jirovecii PCR testing or trimethoprim-sulfamethoxazole (TMP-SMX) initiation.

      HHS, hyperosmolar hyperglycemic syndrome; WBC, white blood cell; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; NA, not available; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; CRP, C-reactive protein; PCR, polymerase chain reaction; CMV, cytomegalovirus; MV, mechanical ventilation; HFNC, high-flow nasal cannula.

      CD4⁺ T-cell subset analysis was available only for case 4 and was obtained at the time of TMP-SMX initiation.


      KMJ : Kosin Medical Journal
      TOP